Skip to main content

Daratumumab and Hyaluronidase-fihj

(DAYR-uh-TOOM-yoo-mab … HY-al-yoo-RAH-nih-days)

This page contains brief information about daratumumab and hyaluronidase-fihj and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.

US Brand Name(s)
Darzalex Faspro
FDA Approved

FDA label information for this drug is available at DailyMed.

Use in Cancer

Daratumumab and hyaluronidase-fihj is approved to be used alone or with other drugs to treat:

Daratumumab and hyaluronidase-fihj is a form of daratumumab that is given as a subcutaneous injection. This form can be given more quickly than daratumumab, which is given as an infusion. This shortens the amount of time it takes to receive each treatment. For more information about daratumumab that may apply to daratumumab and hyaluronidase-fihj, see the Drug Information Summary for Daratumumab.

Daratumumab and hyaluronidase-fihj is also being studied in the treatment of other types of cancer.

More About Daratumumab and Hyaluronidase-fihj

Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.

Research Results and Related Resources

Monoclonal Antibodies

Clinical Trials Accepting Patients

Find Clinical Trials for Daratumumab And Hyaluronidase-fihj - Check for trials from NCI's list of cancer clinical trials now accepting patients.

  • Posted:
  • Updated: